



16 October 2023
EMA/337051/2023 Rev 1.¹

Shortage of Trulicity (dulaglutide) Solution for injection pre-filled pens (0.75, 1.5, 3 and 4.5 mg)	
Indication	<p>Trulicity is a medicine used in addition to diet and exercise in adults and children from 10 years of age who have type 2 diabetes.</p> <p>It is used:</p> <ul style="list-style-type: none">• on its own when use of metformin (another medicine for type 2 diabetes) is not recommended;• as an 'add-on' to other diabetes medicines.
Reason for shortage	<p>There has been an increase in demand for Trulicity, which has led to intermittent supply shortages that are expected to continue at least until end of December 2023.</p> <p>The supply shortage is not related to a quality defect of the product or a safety issue.</p>
Member States affected	<p>Austria, Denmark, Estonia, Finland, Latvia, Lithuania, Norway, Poland and Sweden are currently affected by the shortage.</p> <p>This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, contact the national competent authority.</p>
Monitoring of shortage	<p>EMA's SPOC working party² is closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to identify measures to mitigate the impact of the supply shortage.</p>
Information for healthcare professionals	<ul style="list-style-type: none">• An increase in demand for Trulicity has led to supply shortages that are expected to continue at least until end of December 2023.

¹ This document was initially published on 28 August. It was then modified on 16 October 2023 to update information on the duration of the shortage.

² The [SPOC working party](#) is responsible for monitoring and reporting events that could affect the supply of medicines in the EU. Summaries of the SPOC working party meetings can be found on [EMA's website](#).

**Shortage of Trulicity (dulaglutide)
Solution for injection pre-filled pens (0.75, 1.5, 3 and 4.5 mg)**

	<ul style="list-style-type: none">• Healthcare professionals should ensure that patients at risk of running out of Trulicity are switched in time to a suitable alternative.• Additional advice may be available from your country's national shortage register or national competent authority.
Information for patients	<ul style="list-style-type: none">• An increase in demand for Trulicity has led to supply shortages that are expected to continue at least until end of December 2023.• If you are at risk of running out of Trulicity, your doctor will discuss with you the need to switch to a suitable alternative.• If you have any questions, speak to your doctor or pharmacist.• Additional advice may be available from your country's national shortage register or national competent authority.
Status	Ongoing